Skip to main content

NACFC Main banner

Icon Legend

Food/Drinks Available

CE's Available

Reception

Pre-registration Required

Livestreaming

Recorded Session

EPIDEMIOLOGY & POPULATION-BASED RESEARCH

EPIDEMIOLOGY & POPULATION-BASED RESEARCH

Type here to filter the list

(17) Fetal Impact of CFTR Modulator use during Assisted and Natural Reproduction and Partner Pregnancy in Men with CF

Favorite
(18) Worlds apart: Comparing cystic fibrosis (CF) registry cohorts in South Africa and Canada

Favorite
(19) Analysis of survival in Cystic Fibrosis for a state of Argentina: Five years 2016-2020

Favorite
(20) Impact of Elexacaftor/Tezacaftor/Ivacaftor therapy on older patients with Cystic Fibrosis

Favorite
(21) Feasibility of utilizing a modified menstrual tracking app to correlate menstrual cycles and cystic fibrosis symptoms among women with CF: Early findings of the MENSTRUAL study.

Favorite
(22) Characteristics of Late Diagnosis Through Newborn Screening and Effects on Growth and Pulmonary Health Outcomes in Infants with CF

Favorite
(23) Outcomes of Children with CFTR-Related Metabolic Syndrome (CRMS)

Favorite
(24) Making CF community insights more accessible: An overview on the CF Foundation Community Data Repository

Favorite
(25) Impact of repeated non-treatment on long-term lung function

Favorite
(26) Gingivitis in Children with Cystic Fibrosis

Favorite
(27) The Impact of SARS-CoV-2 on Long-term Physical and Mental Health Symptoms in People with CF and their Caregivers

Favorite
(28) A MULTI-CENTER STUDY of PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC-CF): PREDICTORS of DIFFICULT LINE INSERTION, MALFUNCTION and SOFT TISSUE INJURY

Favorite
(29) Cystic Fibrosis in West Virginia: Is higher BMI target desirable?

Favorite
(30) Factors contributing to successful retention of Cystic Fibrosis patients in a 3-month daily symptom tracking study

Favorite
(31) Sleep Disturbance & School Engagement In Children With Cystic Fibrosis During The COVID-19 Pandemic

Favorite
(32) Characteristics of 225 infants with CFSPID/CRMS identified in New York State over a three-year period

Favorite
(33) Cystic Fibrosis in the United States by 2040: a population landscape analysis

Favorite
(34) The impact of pregnancy on lung function in women with Cystic Fibrosis in the USA and UK: A registry-based study, 2003-2017

Favorite
(35) Approaches that use historical controls to meet modern needs in cystic fibrosis clinical trials

Favorite
(36) Respiratory Outcomes In The Era of High Quality Modulator Therapies: Results from the Tennessee and Mississippi Cystic Fibrosis Consortium

Favorite
(37) Trends in Canadian cystic fibrosis healthcare utilization amidst the COVID-19 pandemic

Favorite
(38) Cutaneous rash with elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis

Favorite
(39) The Relationship Between Post-transfer Outcomes and Continuity of Recommended Care During Healthcare Transition in Cystic Fibrosis

Favorite
(40) An update from MN on the seroprevalence of COVID-19 IgG in our adult population

Favorite
(41) Association of Pseudomonas aeruginosa Infection Stage with Lung Function Trajectory In Children with CF>

Favorite
(43) CFTR Modulator Induced Sweat Chloride Changes Across the Cystic Fibrosis Population from the CHEC-SC Study: 2022 Update

Favorite
(44) Factors associated with the survival of Mexican patients with CF - a Cohort Study.

Favorite
(45) Impact of Early Growth Trajectories and CFTR Modulator Therapy on Puberty in Cystic Fibrosis

Favorite
(46) Lipid Trends on Highly Effective Modulators in Cystic Fibrosis

Favorite
(47) Longitudinal Assessment of Health-related Quality of Life and Clinical Outcomes in Children and Adolescents with Cystic Fibrosis in Australia

Favorite
(48) Longitudinal outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic

Favorite
(49) Medication Adherence and Lung Function Changes with Elexacaftor/Tezacaftor/Ivacaftor Treatment

Favorite
(50) Multi-center cohort study exploring the impact of the first UK COVID-19 lockdown on nebulizer usage amongst adults with cystic fibrosis, within the CFHealthHub learning health system

Favorite
(51) Outcomes following SARS-CoV-2 infection among Canadians living with cystic fibrosis: Analyses using the Canadian Cystic Fibrosis Registry

Favorite
(52) Participation in interventional drug trials among minority populations at an urban adult cystic fibrosis center

Favorite
(53) Pregnancies in women with cystic fibrosis – with or without the intake of elexacaftor/ tezacaftor/ ivacaftor

Favorite
(54) Updated estimates of CF prevalence and participation in the Cystic Fibrosis Foundation Patient Registry in the United States

Favorite
(55) Utilizing Telemedicine in a Cystic Fibrosis Newborn Screening Clinic

Favorite
(56) Vaping and Vaping Exposure in Children, Adolescents, and Young Adults with Cystic Fibrosis: Prevalence and Outcomes

Favorite